#USA #Manufacturing #Cipla #respiratory #Fall River

Cipla Expands Operations in Fall River

Cipla Limited, a prominent pharmaceutical company, has announced its plans to significantly bolster its manufacturing operations in Fall River, Massachusetts. The recent expansion will include an 83,000-square-foot addition to its facility located on Innovation Way, aimed at improving production capacity and operational efficiency. This initiative is part of Cipla's broader strategy to enhance its US manufacturing footprint, particularly focusing on complex respiratory products.

This new facility is expected to incorporate cutting-edge technology and advanced manufacturing processes, which will not only ensure the highest quality standards but also increase efficiency in operations. Cipla's Fall River plant will specialize in the production of respiratory products designed for the US market and will feature state-of-the-art filling capabilities along with stringent quality assurance processes. The workforce at this facility will be specifically trained for complex manufacturing roles, underscoring Cipla's commitment to delivering top-notch respiratory care solutions to patients across the nation.

Marc Falkin, CEO of Cipla North America, stated, "This expansion not only underscores our commitment to manufacturing generic pharmaceuticals in the US market, but also reflects our dedication to supporting the community through job creation and economic development." Cipla currently employs over 800 individuals in the United States and is dedicated to addressing the evolving generic pharmaceutical needs of patients.

In recognition of its expansion efforts, Cipla has been selected as a recipient of the Massachusetts Life Sciences Center (MLSC) tax incentive program. This support will be pivotal in facilitating their expansion in Fall River while simultaneously creating new job opportunities in the region. Moreover, Cipla USA has been recognized as a 'Great Place to Work' for three consecutive years, further enhancing its reputation as an employer of choice.

Cipla is actively hiring for various roles within its expanded operations. Positions are available in manufacturing, quality control, engineering, and operations. The company is planning to hold on-the-spot interviews in the coming weeks, making it easier for prospective candidates to join their team. Individuals interested in applying can visit Cipla's careers page at www.cipla.com to view available positions and submit their applications online.

Founded in 1935, Cipla has established itself as a global pharmaceutical leader that focuses on sustainable growth and complex generics. With a strong presence in key markets including India, South Africa, and North America, Cipla manufactures a diverse portfolio of over 1,500 products across 50+ dosage forms using the latest technology. The company is highly regarded in segments such as respiratory care, anti-retrovirals, urology, and cardiology.

Cipla has achieved notable recognition as a leader in the respiratory segment, standing at #2 in global inhaler sales and within the top 3 for US generic respiratory sales, based on data from IQVIA TRx as of May 2025. The company’s commitment to healthcare dignity and its purpose of "Caring for Life" drives its mission to enhance patient lives and deepen community connections wherever it operates.

For more information regarding Cipla and its bearing on respiratory health, visit their USA website at www.ciplausa.com. This expansion is anticipated to not only enhance Cipla's operational capabilities but also significantly contribute to the local economy by providing numerous employment opportunities and supporting community growth.